Identifying copyright holders and response times are major challenges in COA licensing, causing delays in clinical trials. Clear documentation of copyright ownership and standardized response times ...
Unpack how rising competition for the same high-profile sites is slowing startup and enrollment—and what sponsors must change ...
In today’s ACT Brief, we hear how sponsors may redefine efficiency to protect patient access in 2026, review Verana Health’s ...
In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...
Explore how sponsors can recalibrate efficiency efforts to avoid overconcentrating trials at familiar sites and instead ...
The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...
Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and ...
In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...
In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...
So having a representative population is really important. One part of that is being able to enroll more patients in the ...
Understand which barriers to cancer trial participation remain most difficult to overcome, including geography and trial ...
In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback